UK
Robert King
I am a Senior Consultant at LCP within the Health Analytics team where my role is to provide expertise in health economics.
I have previously worked as a health economist on the development of NICE clinical guidelines, where I ensured cost-effective recommendations along the patient pathways for hip knee and shoulder replacements. Here I also provided economic analysis and modeling for areas where existing evidence was lacking.
I also bring experience in policy evaluation having consulted on European Commission healthcare and legislation. These consultations included EU-level estimates of demand for therapeutic radiopharmaceuticals and analysis of medicine shortages across the European Economic Area.
At LCP I am involved with a wide range of work that includes the design of innovative care pathways that align patient outcomes and stakeholder incentives and helping to source data that can be used to estimate total health and cost impacts. Underpinning much of this work are themes of value-based healthcare and shifting perspectives from single illnesses to multimorbidity.
LCP have a practical way of looking at things and cut through the noise on essential issues.
LCP client
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
